



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/695,577
Filing Date	10/28/2003
First Named Inventor	Edwin R. Chapman
Art Unit	1645
Examiner Name	--
Attorney Docket Number	960296.99004

Sheet	1	of	4
-------	---	----	---

[illegible][illegible]

**Examiner
Signature**

Date Considered

11/26/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual's case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/695,577
Filing Date	10/28/2003
First Named Inventor	Edwin R. Chapman
Art Unit	1645
Examiner Name	—
Attorney Docket Number	960296.99004

Sheet

2

of

4

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MS	1	J. BAI, et al. Membrane-embedded synaptotagmin penetrates cis or trans target membranes and clusters via a novel mechanism. J Biol Chem 275: 25427-35 (2000).	
	2	E.R. CHAPMAN. Synaptotagmin: a Ca(2+) sensor that triggers exocytosis? Nat Rev Mol Cell Biol 3: 498-508 (2002).	
	3	E.R. CHAPMAN, et al. A novel function for the second C2 domain of synaptotagmin. Ca2+-triggered dimerization. J Biol Chem 271:5844-49 (1996).	
	4	D. DEMEMES, et al. Efferent function of vestibular afferent endings? Similar localization of N-type calcium channels, synaptic vesicle and synaptic membrane-associated proteins. Neuroscience 98: 377-84 (2000).	
	5	M. FUKUDA, et al. Mechanism of the SDS-resistant synaptotagmin clustering mediated by the cysteine cluster at the interface between the transmembrane and spacer domains. J Biol Chem 276: 40319-25 (2001).	
	6	M. FUKUDA, et al. Synaptotagmin IX regulates Ca2+-dependent secretion in PC12 cells. J Biol Chem 277: 4601-04 (2002).	
	7	M. FUKUDA, et al. Distinct self-oligomerization activities of synaptotagmin family. Unique calcium-dependent oligomerization properties of synaptotagmin VII. J Biol Chem 275: 28180-85 (2000).	
	8	A. GUT, et al. Expression and localisation of synaptotagmin isoforms in endocrine β -cells: their function in insulin exocytosis. Journal of Cell Science 114(9): 1709-16 (2001).	
	9	P. JUZANS, et al. Synaptotagmin II immunoreactivity in normal and botulinum type-A treated mouse motor nerve terminals. Pflugers Arch 431: R283-84 (1996).	
↓	10	S. KOZAKI, et al. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb Pathog 25: 91-99 (1998).	

Examiner
Signature*Edwin R. Chapman*Date
Considered

11/26/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/695,577
		Filing Date	10/28/2003
		First Named Inventor	Edwin R. Chapman
		Art Unit	1645
		Examiner Name	—
Sheet 3 of 4	Attorney Docket Number	960296.99004	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MS	11	J.L. LEWIS, et al. The transmembrane domain of syntaxin 1A is critical for cytoplasmic domain protein-protein interactions. J Biol Chem 276: 15458-65 (2001).	
	12	L. LI, et al. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J Nat Toxins 7: 215-26 (1998).	
	13	M. MATTEOLI, et al. Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J Cell Biol 117: 849-61 (1992).	
	14	T. NISHIKI, et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269: 10498-503 (1994).	
	15	T. NISHIKI, et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378: 253-57 (1996).	
	16	T. NISHIKI, et al. Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci Lett 208: 105-08 (1996).	
	17	S.L. OSBORNE, et al. Calcium-dependent oligomerization of synaptotagmins I and II. Synaptotagmins I and II are localized on the same synaptic vesicle and heterodimerize in the presence of calcium. J Biol Chem 274: 59-66 (1999).	
	18	M.S. PERIN, et al. Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. Nature 345: 260-63 (1990).	
	19	G. SCHIAVO, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832-35 (1992).	
✓	20	G. SCHIAVO, et al. Synaptotagmins: more isoforms than functions? Biochem Biophys Res Commun 248: 1-8 (1998).	

Examiner Signature	<i>Janessa Ford</i>	Date Considered	11/26/05
--------------------	---------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/695,577
Filing Date	10/28/2003
First Named Inventor	Edwin R. Chapman
Art Unit	1645
Examiner Name	--
Attorney Docket Number	960296.99004

Sheet

4

of

4

OTHER PRIOR ART--NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>MA</i>	21	C.T. WANG, et al. Synaptotagmin modulation of fusion pore kinetics in regulated exocytosis of dense-core vesicles. Science 294: 1111-15 (2001).	
	22	GenBank Accession No. P24506.	
	23	GenBank Accession No. P24505.	
	24	GenBank Accession No. P47191.	
	25	GenBank Accession No. NP_005630.	
	26	GenBank Accession No. X52772.	
	27	GenBank Accession No. D37793.	
	28	GenBank Accession No. D37792.	
	29	GenBank Accession No. M64488.	
	30	GenBank Accession No. Q8N910.	

Examiner
Signature*James A. Ford*Date
Considered*11/26/05*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/695,577
		Filing Date	October 28, 2003
		First Named Inventor	Edward R. Chapman
		Art Unit	1645
		Examiner Name	N/A FORD
Sheet 2 of 2	Attorney Docket Number	960296.99004	

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MS		M. Fukuda, et al., "Inositol-1,3,4,5-tetrakisphosphate Binding to C2B Domain of IP4BP/Synaptotagmin II," J. Biol. Chem. 269(46):29206-29211, 1994.	
↓		J. T. Littleton and H. J. Bellen, "Synaptotagmin Controls and Modulates Synaptic-vesicle Fusion in a Ca ²⁺ -dependent Manner," TINS 18(4):177-183, 1995.	
↓		W. D. Matthew, et al., "Identification of a Synaptic Vesicle-specific Membrane Protein with a Wide Distribution in Neuronal and Neurosecretory Tissue," J. Cell Biol. 91:257-269, 1981.	
↓		Y. Shoji-Kasai, et al., "Neurotransmitter Release from Synaptotagmin-deficient Clonal Variants of PC12 Cells," Science 256(5065):1820-1823, 1992.	

Examiner Signature		Date Considered	11/26/05
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.